科济药业基于其自主研发的THANK-uCAR 通用型CAR-T技术，开发了升级版的THANK-u Plus平台，以克服NKG2A表达水平对疗效可能的影响。在不同NKG2A表达水平NK细胞的存在下，THANK-u Plus均可持续扩增，并且扩增水平较THANK-uCAR显著提升。动物实验显示，THANK-u Plus在NK细胞存在下的抗肿瘤疗效显著优于THANK-uCAR。在此平台下的同种异体BCMA或CD19/CD20双靶CAR-T在NK存在时都显示出极强的抗肿瘤疗效，表明该平台可广泛用于多种通用型CAR-T细胞的研制。Shanghai, December 31, 2024 /PR Newswire/ -- KJD Pharmaceutical (Stock Code: 2171.HK), an innovative CAR-T cell therapy company mainly focused on treating hematological malignancies and solid tumors, announced that its self-developed universal CAR-T cell therapy candidate product KJ-C2219 targeting CD19/CD20 has initiated an investigator-initiated clinical trial (IIT) in China for refractory/relapsed B-cell non-Hodgkin lymphoma (R/R B-NHL).
KJ-C2219 is developed based on the THANK-u Plus platform and is intended for the treatment of hematological malignancies and autoimmune diseases.
About THANK-u Plus
KJD Pharmaceutical has developed an upgraded THANK-u Plus platform based on its self-developed THANK-uCAR universal CAR-T technology to overcome the potential impact of NKG2A expression levels on efficacy. THANK-u Plus can sustain expansion in the presence of NK cells at different NKG2A expression levels, and the expansion level is significantly higher than that of THANK-uCAR. Animal experiments show that THANK-u Plus exhibits significantly better anti-tumor efficacy in the presence of NK cells compared to THANK-uCAR. Allogeneic BCMA or CD19/CD20 dual-target CAR-T under this platform shows extremely strong anti-tumor efficacy in the presence of NK cells, indicating that this platform can be widely used for the development of various universal CAR-T cells.
About Keji Pharmaceutical.
SciClone Pharmaceuticals (stock code: 2171.HK) is a biopharmaceutical company with business in China and the USA, primarily focused on innovative CAR-T cell therapies for the treatment of hematological malignant tumors and solid tumors. The company has established a CAR-T cell research and development platform ranging from target discovery and innovative CAR-T cell development, clinical trials, and commercial-scale production. The company aims to address major challenges facing current CAR-T cell therapies, such as improving safety, increasing efficacy in treating solid tumors, and reducing treatment costs, by independently developing new technologies and possessing a global product pipeline. The mission of SciClone Pharmaceuticals is to become a global leader in the biopharmaceutical field, providing innovative and differentiated cell therapies to cancer patients worldwide and enabling cancer to be cured.
Forward-looking statement
All statements in this press release that do not relate to historical facts or are not relevant to current facts or conditions are forward-looking statements. Such forward-looking statements express the Group's current views, forecasts, beliefs, and expectations regarding future events as of the date of this press release. These forward-looking statements are based on certain assumptions and factors that the Group cannot control. Therefore, they are subject to significant risks and uncertainties that could cause actual events or results to differ materially from those in these forward-looking statements, and the forward-looking events discussed in this press release may not occur. These risks and uncertainties include but are not limited to the details under the title 'Major Risks and Uncertainties' in our recent annual reports, interim reports, and other announcements and reports published on our company website. No representations or warranties are made regarding the achievement or reasonableness of any forecast, target, estimate, or prediction contained in this press release, and reliance on such forecasts should not be placed.
Contact Keji Pharmaceuticals.
For more information, please visit the company website:
